IWD - iShares Russell 1000 Value ETF
121.42 +0.04 (0.03%)
After hours: 4:00PM EDT
| Previous Close | 120.93 |
| Open | 121.10 |
| Bid | 121.36 x 400 |
| Ask | 121.42 x 100 |
| Day's Range | 120.72 - 121.77 |
| 52 Week Range | 112.39 - 131.56 |
| Volume | 1,577,655 |
| Avg. Volume | 2,106,324 |
| Net Assets | 36.23B |
| NAV | 119.95 |
| PE Ratio (TTM) | N/A |
| Yield | 2.25% |
| YTD Return | -2.97% |
| Beta (3y) | 0.96 |
| Expense Ratio (net) | 0.20% |
| Inception Date | 2000-05-22 |
- Zacks•yesterday
Should OShares FTSE U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?
Style Box ETF report for OUSA
- Zacks•8 days ago
Should iShares Edge MSCI Multifactor USA ETF (LRGF) Be on Your Investing Radar?
Style Box ETF report for LRGF
- Zacks•9 days ago
Should First Trust Rising Dividend Achievers ETF (RDVY) Be on Your Investing Radar?
Style Box ETF report for RDVY
- Zacks•14 days ago
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
Style Box ETF report for IWX
- Barrons.com•20 days ago
[$$] The Best Actively Managed ETFs
If you’re a fan of active management, there’s ample reason to like the Fidelity Total Bond mutual fund. It’s Gold-rated by Morningstar and has beaten the Bloomberg Barclays US Aggregate Bond Index by one percentage point annually over the past 10 years. At Charles Schwab, for instance, buying the Fidelity mutual fund (FTBFX), which isn’t on Schwab’s no-transaction-fee OneSource platform, costs $76.
- Forbes•23 days ago
Investment Strategies To Improve On Passive U.S. Indexing
For many, passive indexing against a robust U.S. index is a sound strategy. But academic research suggests there may be a view ways to improve risk-adjusted returns beyond this. We explore implementing these strategies with popular ETFs.
- Zacks•last month
March Madness ETF Prediction and Sweet 16 Picks
The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.
- Barrons.com•last month
Wait for a Bear Before Loading Up on Foreign Stocks
Waiting for a bear market may seem like waiting for Godot—it’s been 3,297 days since the last bear market ended on March 9, 2009. Ramsey points out that foreign stocks in the MSCI EAFE index have been lagging the U.S. market this year, and they now trade at 26% discount to the MSCI USA index based on “normalized” price/earnings ratios (which smooth out the volatility in earnings over multi-year periods). The EAFE traded at the same discount in May 2010—the start of an “epic phase of underperformance” compared with the U.S. market, he says in a recent blog post.
- Barrons.com•3 months ago
Where To Find Cover In Market Meltdown? Not The Usual Spot
The cornerstone of asset allocation has been that bonds offer a buffer to stocks when they tumble. Two quant strategists took a closer look at where investors may want to seek cover: Pavilion Global Market’s quantitative macro analyst Antoine Naly says bonds have not always acted as a buffer for stock meltdowns. Going back to the 19 century, Naly says correlations between bond and equity returns sometimes turn positive—and for long periods of time too, when inflation rates were rising like in the 1970s. While Naly says we are a long ways off from those rates, there is evidence to suggest we are moving toward a more inflationary period, at least on a cyclical basis.
- Zacks•3 months ago
Wall Street Sees Worst Sell-Off in Years: 5 ETF Buying Zones
The latest sell-off could prompt investors to re-access their portfolio.
Market Realist•3 months agoWhy Abbott Laboratories Plans to Focus on Organic Growth in 2018
Abbott Laboratories (ABT) released its 4Q17 and fiscal 2017 earnings results on January 24, 2018. Abbott seems quite confident about its strong product pipeline and recent product launches. In 2017, Abbott Laboratories launched a number of innovative products and expanded across geographies and business segments.
Market Realist•3 months agoZBH’s Latest 1Q18 Guidance: What You Need to Know
Zimmer Biomet Holdings' 4Q17: Sales Beat, Earnings Meet
InvestorPlace•3 months agoThe 10 Most Expensive Stocks In The S&P 500
Last week I highlighted the Top 10 Value Stocks In The S&P 500 noting that “value will have its day in the sun” in 2018. But what are the S&P 500’s most expensive stocks?
- CNBC•3 months ago
This year's 'best' trades still deeply in the hole as crowd rushes in
Large-cap and growth stocks continue to beat small-caps and value, even though everyone thought the tide would turn this year.
- Market Realist•3 months ago
How Is Bristol-Myers Squibb’s Sprycel Positioned for 2018?
What Could Drive Bristol-Myers Squibb in 2018?
Market Realist•3 months agoWhy Opdivo Could Continue to Be Growth Driver beyond 2018
What Could Drive Bristol-Myers Squibb in 2018?
- ETF Trends•5 months ago
Value ETF Style is Back in Vogue
Growth stocks have surged this year in the ongoing post-election rally, but more recently, the value style and related exchange traded funds are beginning to pull ahead. Year-to-date, the iShares Russell ...
- Market Realist•5 months ago
Can Smart Beta Go Wrong?
The smart beta approach aims to benefit from market inefficiencies to deliver higher risk-adjusted returns and improve diversification.
- Investor's Business Daily•6 months ago
Stocks Mixed As Biotechs Dive; Buffett Stocks Near Buy Point?
Stocks were mixed as Amgen and Celgene hurt biotechs, and ahead of ahead of Amazon and Alphabet's earnings after the close.
- CNBC•7 months ago
The value stock comeback could be a bad sign for the market
Value is outperforming growth in the last month, and that could be the "canary in the coal mine," said Gina Sanchez.
- Market Realist•7 months ago
Mylan and Multiple Partnerships to Advance Biosimilar Portfolio
In 2017, Mylan (MYL) plans to submit BLAs to the FDA for the approval of biosimilars for trastuzumab, pegfilgrastim, bevacizumab, adalimumab, and insulin glargine.
